Biofron­tera will yank shares from Nas­daq; In­tel­lia and ONK col­lab­o­rate on can­cer can­di­dates

Ger­man bio­phar­ma Biofron­tera has de­cid­ed to delist its shares from the Nas­daq and dereg­is­ter its re­port­ing oblig­a­tions with the SEC in an at­tempt to re­duce com­plex­i­ty in fi­nan­cial re­port­ing and ad­min­is­tra­tive costs.

The com­pa­ny’s or­di­nary shares will still be trad­ed in the Prime Stan­dard at the Deutsche Börse un­der the sym­bol B8F. Amer­i­can share­hold­ers can choose to ex­change their Amer­i­can De­posi­tary Shares for or­di­nary shares on the Deutsche Börse, the com­pa­ny said in a re­lease.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER